SpringWorks Therapeutics, Inc. (SWTX)

NASDAQ: SWTX · Real-Time Price · USD
36.35
-0.79 (-2.13%)
At close: Dec 27, 2024, 4:00 PM
36.27
-0.08 (-0.22%)
After-hours: Dec 27, 2024, 4:30 PM EST
-2.13%
Market Cap 2.70B
Revenue (ttm) 135.49M
Net Income (ttm) -275.16M
Shares Out 74.37M
EPS (ttm) -3.83
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 599,734
Open 36.82
Previous Close 37.14
Day's Range 35.73 - 37.40
52-Week Range 28.21 - 53.92
Beta 0.79
Analysts Strong Buy
Price Target 67.00 (+84.32%)
Earnings Date Feb 25, 2025

About SWTX

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Sep 13, 2019
Employees 305
Stock Exchange NASDAQ
Ticker Symbol SWTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for SWTX stock is "Strong Buy." The 12-month stock price forecast is $67.0, which is an increase of 84.32% from the latest price.

Price Target
$67.0
(84.32% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Tarsus Pharmaceuticals & SpringWorks Therapeutics: Jonathan Faison's Top 2 Picks

Jonathan Faison runs the ROTY Biotech Community. Why he's high on Tarsus Pharmaceuticals and his #1 holding, SpringWorks Therapeutics.

Other symbols: TARS
14 days ago - Seeking Alpha

SpringWorks Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference

STAMFORD, Conn., Nov. 26, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announc...

4 weeks ago - GlobeNewsWire

SpringWorks Therapeutics, Inc. (SWTX) Q3 2024 Earnings Call Transcript

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Q3 2024 Earnings Call November 12, 2024 8:30 AM ET Company Participants Kim Diamond - Vice President, Corporate Communications Saqib Islam - Chief Executi...

6 weeks ago - Seeking Alpha

SpringWorks Therapeutics to Participate in the Jefferies London Healthcare Conference

STAMFORD, Conn., Nov. 12, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announc...

6 weeks ago - GlobeNewsWire

SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

– Achieved $49.3 million in OGSIVEO ® (nirogacestat) net product revenue in the third quarter –

6 weeks ago - GlobeNewsWire

SpringWorks Therapeutics Announces Mirdametinib Data to be Presented at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting

– Data from the pivotal Phase 2b ReNeu trial demonstrate that patients with NF1-PN achieved deep responses and improvements in health-related quality of life over the course of mirdametinib treatment ...

6 weeks ago - GlobeNewsWire

SpringWorks Therapeutics Announces Publication of the Pivotal Phase 2b ReNeu Trial Evaluating Mirdametinib in Adults and Children with NF1-PN in the Journal of Clinical Oncology

– Mirdametinib treatment demonstrated significant confirmed objective response rates and a  manageable safety profile in adults and children with NF1-PN –

6 weeks ago - GlobeNewsWire

SpringWorks Therapeutics Announces Long-Term Efficacy and Safety Data from Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors to be Presented at the Connective Tissue Oncology Society (CTOS) 2024 Annual Meeting

– Long-term follow-up data highlight further reductions in tumor size, increase in ORR with additional CRs, sustained improvement in desmoid tumor symptoms, and consistent safety profile, now with a m...

7 weeks ago - GlobeNewsWire

SpringWorks Therapeutics to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

STAMFORD, Conn., Nov. 05, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announc...

7 weeks ago - GlobeNewsWire

SpringWorks Therapeutics Merits A Speculative Buy

Since we last visited with SpringWorks Therapeutics, Inc. in the summer of 2023, the company has garnered its first FDA approval. That drug has seen encouraging initial sales, and management recently ...

7 weeks ago - Seeking Alpha

SpringWorks Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

STAMFORD, Conn., Oct. 22, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announc...

2 months ago - GlobeNewsWire

FDA Grants Priority Review to SpringWorks Therapeutics' New Drug Application for Mirdametinib for the Treatment of Adults and Children with NF1-PN

– PDUFA target action date of February 28, 2025 – – EU Marketing Authorization Application also validated by European Medicines Agency – STAMFORD, Conn., Aug. 28, 2024 (GLOBE NEWSWIRE) -- SpringWorks ...

4 months ago - GlobeNewsWire

SpringWorks Therapeutics Recent Developments Move This To Speculative Buy (Upgrade)

Investment merits have increased materially since my last article with more support for its approved therapy and pipeline advancements. Ample liquidity supports its operations and pipeline development...

5 months ago - Seeking Alpha

SpringWorks Therapeutics: Rising On A Strong Post-Launch Quarter, Now Justified As A Buy

SWTX's market confidence has increased post-launch, with $40.2 million in product revenue and $19.5 million in collaboration revenue in the first quarter. Nirogacestat approval for desmoid tumors and ...

5 months ago - Seeking Alpha

SpringWorks Therapeutics, Inc. (SWTX) Q2 2024 Earnings Call Transcript

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Q2 2024 Earnings Conference Call August 7, 2024 8:30 AM ET Company Participants Samantha Sandler - Senior Director of IR Saqib Islam - CEO Bhavesh Ashar -...

5 months ago - Seeking Alpha

SpringWorks Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

– Achieved $40.2 million in OGSIVEO ® (nirogacestat) net product revenue in the second quarter –

5 months ago - GlobeNewsWire

SpringWorks Therapeutics Appoints Dr. Martin Mackay to its Board of Directors

STAMFORD, Conn., July 29, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announc...

5 months ago - GlobeNewsWire

SpringWorks Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024

STAMFORD, Conn., July 23, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announc...

5 months ago - GlobeNewsWire

Kuehn Law Encourages Investors of SpringWorks, Therapeutics Inc. to Contact Law Firm

NEW YORK , July 2, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) bre...

6 months ago - PRNewsWire

SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN

STAMFORD, Conn., July 01, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced tod...

6 months ago - GlobeNewsWire

SpringWorks Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

STAMFORD, Conn., June 05, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announc...

7 months ago - GlobeNewsWire

SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

– Results from pivotal Phase 2b ReNeu trial of mirdametinib in patients with NF1-PN to be presented in an oral presentation –

7 months ago - GlobeNewsWire

SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference

STAMFORD, Conn., May 08, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announce...

8 months ago - GlobeNewsWire

SpringWorks Therapeutics, Inc. (SWTX) Q1 2024 Earnings Call Transcript

Start Time: 08:30 January 1, 0000 9:06 AM ET SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Q1 2024 Earnings Conference Call May 02, 2024, 08:30 AM ET Company Participants Saqib Islam - CEO Francis Per...

8 months ago - Seeking Alpha

SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates

– Achieved $21.0 million in OGSIVEO ® (nirogacestat) net product revenue in the first quarter –

8 months ago - GlobeNewsWire